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using a Kruskal-Wallis test with a Dunn’s multiple comparison test; a
Mann Whitney t test was used for cartilage. P < 0.05 was considered
signiﬁcant. All procedures were approved by institutional animal care
and use committees.
Results: Osteochondral fragments were successfully created and multiple
clinical and morphologic changes consistent with early OA were
demonstrated. OC injured horses exhibited a decrease in forelimb
symmetry (P < 0.001) at week 2 on the force plate, indicating pain. No
further differences were seen over time or between groups. By week 16,
range of motion decreased in 9/11 (82%) OC injured limbs compared to
no change in sham and control limbs. Subjective joint effusion scores
increased in OC injured limbs compared to baseline throughout the
entire study period (P < 0.001). Radiographic scores showed subtle but
signiﬁcant change in the OC injured limbs (Table 1). Arthroscopically,
synovial membrane from OC injured joints exhibited mild changes
(hyperemia, villus thickening, and proliferation). However, cartilage
damage within the joint was more pronounced (Table 1). Histologically,
chondrocyte necrosis and proliferation (repair) were signiﬁcantly greater
in OC injured cartilage compared to sham cartilage, with the majority of
changes restricted to the superﬁcial zone (Table 1). A non-inﬂammatory
ﬁbrotic reaction was seen in OC injured synovium.
Conclusions: Creation of an OC fragment in the equine MCP joint results
in acute traumatic joint injury that has mild but consistent clinical and
morphological features of early OA. This non-terminal injury model will
be useful for deﬁning biomarker changes of early OA and for monitoring
response to therapy of this disease.
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EX-VIVO EFFECTS OF MELOXICAM ON CHONDROCYTE METABOLISM
IN OSTEOARTHRITIC CANINE CARTILAGE
S. Budsberg1, A. Stoker2, S. Johnston1, S. Johnston1, W. Liska3,
L. Reynolds1, J. Cook2. 1Univ. of Georgia, Athens, GA, USA; 2Univ. of
Missouri-Columbia, Columbia, MO, USA; 3Gulf Coast Vet. Specialists,
Houston, TX, USA
Purpose: This study assessed the effect of meloxicam on chondrocyte
metabolism in a naturally occurring osteoarthritic (OA) canine cartilage
model.
Methods: Cartilage harvest from 21 dogs with coxofemoral OA at time of
total hip replacement (THR). Sixteen dogs did not receive NSAIDs prior
to THR and cartilage harvest (Group 1). Five dogs received meloxicam
for at least 14 days prior to THR and cartilage harvest (Group 2).
Cartilage Explant Culturing: Group 1 – Cartilage with control
0.0ug/ml(Cm:control) and meloxicam media dilutions (0.3, 3.0, 30.0
ug/ml): Explants and media were collected on days 3, 12, and 30.
Group 2 – Cultured with culture medium alone (MPM:Cm).
Tissue Matrix Analysis: (1) surgical sample and (1) explant from each
animal in each test group were collected on days 3, 12, and 30 of
culture and analyzed for total sulfated GAG, total collagen content via
hydroxyproline (HP) measurement and cartilage DNA content.
Media Analysis: Chondroitin sulfate 846 (CS-846), Nitric oxide (NO),
Prostaglandin E2 (PGE2), Matrix metalloproteinases (MMP-2, -3, -13),
Aggrecan and Collagen II, Proteinases (MMP-1, -2, -3, -9, -13,
aggrecanase-1, aggrecanase-2), Proteinase inhibitors (TIMP-1, -2, -3),
Inﬂammatory indicators (IL-1b, TNF-a, COX-1, COX-2 and INOS), House
keeping gene (GAPDH)
Statistical Analysis: For comparisons between group 1 subgroups
(Cm:control) and (Mm0.3, Mm3.0, and Mm30.0) where subgroups
included the same dogs, a repeated measures model was utilized.
For comparisons between MPM:Cm, and Cm:control where each group
included different dogs, an analysis of variance (ANOVA) test was used.
Multiple comparisons were adjusted using Tukey’s test. Signiﬁcance level
was set at a = 0.05.
Results:
In vitro:
– Cartilage matrix analysis: Meloxicam had no effect on GAG, HP
or DNA content compared between Cm:control, Mm 0.3, 3.0, 30.0
subgroups at any time point.
– Media analysis: Signiﬁcant changes: GAG decreased in all group1
subgroups on days 12 and 30 compared to day 3. CS-846 decreased
between day 3 and days 12 and 30 in the Cm:control subgroup.
PGE2 was lower on day 3 in all three meloxicam treated subgroups
compared to Cm:control. Aggrecan was greater days 12 and 30
compared to day 0 for the Cm:control group. MMP-3 was decreased
in Mm0.3, 3.0, 30.0 subgroups between days 3 and 30. Aggrecanase-2
was decreased in all group 1 subgroups on all days compared
to baseline. INOS decreased in all group 1 subgroups on all days
compared to day 0.
Ex vivo:
– Cartilage matrix analysis: Meloxicam pretreatment had no effect on
GAG, HP or DNA content compared between Cm:control, at any time
point.
– Media analysis: Meloxicam pretreated cartilage showed no
differences within or between MPM:cm and Cm:control groups in
GAG, HP or DNA content at any time point. NO – increase in MPM:cm
media on day 3 compared to Cm:control. PGE2 – decrease from day 3
to day 30 in both groups. Proteinases – Media MMP-3 concentrations
were less days 12 and 30 compared to day 3 in the MPM:cm group.
Media MMP-13 was greater in MPM:cm compared to Cm:control on
days 3 and 12. Gene Expression – Cm:control MMP2 was increased
days 3, 12, and 30 compared to day 0. MPM:cm group MMP-2 was
lower than Cm:control on days 3 and 12. Inﬂammatory Indicators –
COX-2 gene expression was greater day 3 compared to day 30 in the
MPM:cm group.
Conclusions: These data suggest that meloxicam treatment of naturally
occurring OA cartilage did not induce degradation over 30 days of
treatment and in some measures (media CS-846 and MMP-3) appeared
to prevent degradation at concentrations up to 100 times the expected
synovial concentrations. Meloxicam effectively decreased inﬂammatory
mediator production (PGE2) in OA chondrocytes. Ex-vivo pretreatment
of OA cartilage with meloxicam did not appear to induce degradative
processes in the cartilage as the cartilage was evaluated for 30 days
following removal of drug.
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Background: Osteoarthritis is a highly prevalent disease, age being the
main risk factor. The age related accumulation of advanced glycation
endproducts (AGEs) adversely affects the mechanical and biochemical
properties of cartilage.
Purpose: The hypothesis that accumulation of cartilage AGEs predispose
to the development of osteoarthritis was tested in vivo in a canine
model.
Methods: To artiﬁcially increase cartilage AGEs, right knee joints of 8
dogs were repeatedly injected with ribose/threose in PBS, left joints with
PBS alone as a control. Subsequently minimal surgically applied cartilage
damage was induced and loading restrained as much as possible.
Thirty weeks after surgery joint tissues of all dogs were analyzed for
biochemical (PG turnover), macroscopic, and histological features of OA.
The Utrecht University Medical Ethical Committee for animal studies
approved the study.
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Results: Cartilage pentosidine (a marker of AGE) levels were ~5 fold
enhanced (p =0.001 vs. PBS injected joints). The macroscopic and
microscopic damage was similar for the AGEd and PBS injected joints
(macroscopic score of 1 of a max score of 4 and histological OARSI score
of 3–5 of a max score of 36, respectively). For the PG synthesis (5.09±0.29
vs 4.64±0.32) % total and newly formed PG (23.29±1.88 vs 23.66±2.02
and 43.02±2.23 vs 43.75±2.4), as well as the PG content (31.20±1.17
vs 30.83±0.98) no statistically difference could be found between both
groups. This was not expected and therefore no control (untouched)
and OA (experimentally induced according to the classic Groove model)
joint were included in the study. Therefore, the biochemical data were
compared to historical controls of the most recent study using the Groove
model. Comparing these results, it demonstrates that the AGEd joints
are in general in between the PBS injected joints and the experimental
early OA joints (for example PG content 31.20±1.17 vs 30.83±0.98 vs
30.44±1.52). The PBS injected joints are in between the normal healthy
joints and the AGEd joints. Assuming a stepwise increase in severity of
damage there was a clear correlation between severity of damage and the
different conditions from healthy control joints, via PBS injected joints
with minimally surgically damage, AGEd joints with minimal surgical
damage, to experimentally induced OA joints according to the Groove
model (PG synthesis r = −0.873, % total and newly formed PG release
r = 0.971, p = 0.029 and r = 0.954, p = 0.046, and PG content r = 0.836).
Conclusions: Despite the fact that enhanced cross-linking of
macromolecules by the AGEs restrains loss of proteoglycans,
corroborating the diminished turnover of old cartilage, and a tendency
toward enhanced cartilage damage in the artiﬁcially aged joints, the
present data do not clearly support a role for enhanced cartilage AGE
levels in development of joint degeneration.
Biomarkers
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A UNIQUE DEAMIDATED CARTILAGE OLIGOMERIC MATRIX
PROTEIN (COMP) BIOMARKER PREFERENTIALLY IDENTIFIES HIP
OSTEOARTHRITIS
J. Catterall1, M-F. Hsueh1, T.V. Stabler1, J.M. Renner2, J.M. Jordan2,
V.B. Kraus1. 1Duke Univ., Durham, NC, USA; 2UNC, Chapel Hill, NC, USA
Purpose. As extracellular proteins age, they undergo and accumulate
non-enzymatic post-translational modiﬁcations that cannot be repaired.
As a tissue, such as cartilage, with a relatively slow protein turnover
ages, the levels of these modiﬁed proteins will increase. This allows the
exciting possibility of being able to distinguish “older” matrix proteins
released by catabolism, from turnover of newly synthesized proteins
or proteins released during times of frustrated repair. We hypothesized
that these modiﬁed proteins could be used to systemically monitor
loss of extracellular matrix due to chronic arthritic diseases such as
osteoarthritis (OA).
Method. To test this hypothesis, we predicted sites of deamidation in
human cartilage oligomeric matrix protein (COMP) and conﬁrmed, by
mass spectroscopy, the presence of deamidated (Asp64) and native
(Asn64) COMP epitopes [mean 0.95% deamidated COMP (D-COMP)
relative to native COMP] in cartilage. We developed monoclonal
antibodies speciﬁc to the deamidated Asp64 COMP region and a D-COMP
speciﬁc ELISA using the 6–1A12 monoclonal antibody, one of our newly
developed D-COMP speciﬁc antibodies. This new ELISA was used to
measure D-COMP in extracts from human cartilage and in human serum
to determine the utility of D-COMP as a novel biomarker for OA. For
comparison we determined the levels of serum Total COMP by ELISA
(antibodies 16-F12 and 17-C10). Cartilage extracts were prepared from
Duke IRB approved surgical waste cartilage, by grinding under liquid
nitrogen, two 4M Guanidine-HCL extractions before dialysis into PBS.
Results. In the Duke BAJA joint replacement study (n =14, mean age
63.4±13.2 yrs; 64% men; 4 hip and 10 knee replacements), serum
D-COMP (p =0.017), but not Total COMP (p =0.5), declined signiﬁcantly
after replacement suggesting an association of serum D-COMP levels with
OA joints. In 450 participants from the Johnston County Osteoarthritis
Project, D-COMP was associated with hip (p < 0.0001) but not knee
(p =0.95) OA severity as deﬁned by increasing Kellgren-Lawrence (KL)
grade. In contrast, Total COMP was associated with knee (p < 0.0001) but
not hip (p =0.47) KL grade. To further investigate D-COMPs association
with hip OA, we determined Total and D-COMP levels in hip (n =11; mean
age 77.3±11.3; 57–90 yrs) and knee cartilage extracts (n = 15; mean age
66.5±8.9; 54–88 yrs). D-COMP was higher in cartilage soluble proteins
extracted from hip proximal to OA lesions compared to macroscopically
normal hip (p = 0.007), or macroscopically normal and OA knee (p < 0.01)
cartilage. Total COMP did not vary by joint site or proximity to the
lesion.
Conclusions. Enrichment of deamidated epitope in hip cartilage likely
indicates a lesser repair response of hip compared with knee cartilage.
This study demonstrates the presence of D-COMP in articular cartilage
and the systemic circulation and to our knowledge, is the ﬁrst biomarker
to show speciﬁcity for a particular joint site.
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Purpose: Several OA biomarkers are currently in development at
different validation stages. Unfortunately, there is no proven method
or test available to identify individuals at risk of developing primary OA,
or to identify which of the affected individuals may require treatment
due to the risk of disease progression. In this context, we have previously
identiﬁed Pitx1, a homeobox transcription factor, as a relevant OA
candidate gene. Indeed, a loss of PITX1 expression was determined
in patients suffering from primary knee joint OA. Recently, we have
identiﬁed Prohibitin (PHB1) as part of the transcriptional repressor
complex turning-off PITX1 expression in OA. Taking into account the
postulated role for PHB1 in cellular senescence and mitochondria
functions, it is conceivable that aberrant nuclear accumulation of PHB1
in primary OA could be detected not only in articular chondrocytes but
also in other cell types especially if this event is caused by genetic
predispositions.
Methods: To verify this assumption, cytosolic and nuclear fractions of
lymphocytes obtained from 88 consecutive OA patients and 33 aged-
matched control subjects were performed by Western blot while nuclear
localization of PHB1 in lymphocytes of OA patients (surgical cases)
was also detected using immunoﬂuorescence methods and confocal
microscopy. Plasma PHB1 levels were determined by an ELISA assay.
Results: Increased nuclear localization of PHB1 in lymphocytes of
OA patients (surgical cases) was detected by Western blot and
immunoﬂuorescence methods when compared to age-matched healthy
controls. Moreover, elevation in the number of nuclear aggregates
positive for PHB1 correlated with disease severity (KL score).
Interestingly, mean plasma PHB1 levels were signiﬁcantly decreased
in OA patients with an average value of 15.8 ng/ml and 21.4 ng/ml for
knee OA and hip OA groups when compared to the healthy control group
(30.1 ng/ml). This reduction in circulating PHB1 levels could be explained
by its nuclear retention.
Conclusions: Here we report a molecular mechanism that can help
to better stratify OA patients and the usefulness of PHB1 as OA
blood biomarker. Furthermore, our clinical data have the merit of
unifying previous concepts and ﬁndings proposed to better deﬁne OA
pathogenesis, such as mitochondrial dysfunction or cellular aging.
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Purpose: Viscosupplementation (VS) by intra articular (IA) injection
of hyaluronic acid (HA) is used to reduce pain in patients with knee
